Nurix Therapeutics, Inc. (NRIX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$26.14+3.24%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · NRIX
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 7.7% |
| Our one-year growth estimate | diamond | -60.0% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 67.7 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 399 industry peers
NRIX — earnings miss
Dated 2026-07-09
Results of Operations and Financial Condition. On July 9, 2026, Nurix Therapeutics, Inc., a Delaware corporation (the “Company”), issued a press release announcing the Company’s financial results for the fiscal quarter ended May 31, 2026. The press rele ase is furnished as Exhibit 99.1 and is incorporated herein by reference. The information furnished with this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as…
Why it matters: Good data could prove bexobrutideg works well and show its market potential.
Watch forClinical data shows an objective response rate over 85% in CLL patients.
Also watch forData shows a big drop in effectiveness, with an objective response rate under 75%.
Why it matters: Revenue growth is important for Nurix's finances. It helps build trust with investors.
Worry ifQ2 revenue shows growth year over year, exceeding current low expectations.
Less concerning ifQ2 revenue declines or grows less than 5% year over year.
Why it matters: Higher operating income shows better cost control. This leads to a more efficient business.
Supportive ifOperating income is rising, moving up from its current low levels.
Worry ifOperating income keeps falling or stays the same.
Why it matters: Starting the Phase 3 trial is key for full approval. It shows progress in development.
Supportive ifNurix starts the Phase 3 DAYBreak CLL-306 trial as planned.
Worry ifThe trial start is delayed or canceled. This raises worries about the drug's progress.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$153 on $10,000 · ±1.5% | How much price usually moves either way. |
| Bad day | $513 loss on $10,000 · 5.1% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $3,279 loss on $10,000 · 32.8% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: More losses in operating income would show that Nurix's finances are getting worse.
Worry ifOperating income fell more from -$92.5 million in 2026-Q1.
Less concerning ifOperating income gets better or stays the same.
Why it matters: These results will provide insights into revenue trends and operating losses. They are critical for assessing financial health.
Watch forRevenue has a big increase compared to the last quarter.
Also watch forRevenue keeps falling or stays the same compared to the last quarter.
Why it matters: Starting this trial is key for Nurix. It aims to get full approval for bexobrutideg.
Supportive ifThe Phase 3 DAYBreak CLL-306 trial is initiated as planned by mid-2026.
Worry ifThe trial initiation is delayed beyond mid-2026 or is canceled.
Why it matters: This trial is important for Nurix to get fast approval for bexobrutideg. Success in enrollment shows strong demand.
Supportive ifEnrollment reaches at least 80% of target patients by the end of Q3 2026.
Worry ifEnrollment remains below 50% of target patients by the end of Q3 2026.
Why it matters: New data from this trial could show how well bexobrutideg works in earlier treatments.
Watch forThe trial shows high objective response rates in earlier lines of therapy.
Also watch forThe trial results show low response rates or safety concerns.
Why it matters: Earnings results will show the effects of the Roche partnership and trials.
Worry ifQ3 earnings show revenue growth or a significant reduction in net loss compared to Q2.
Less concerning ifQ3 earnings report shows continued revenue decline or increased net loss.
Why it matters: Revenue trends will show if Nurix can stop its falling revenue.
Watch forQ3 2026 revenue shows growth compared to Q2 2026.
Also watch forQ3 2026 revenue continues to decline compared to Q2 2026.
Why it matters: Good results could help speed up approval for bexobrutideg in CLL. This affects growth.
Supportive ifThe DAYBreak CLL-201 trial shows positive data. It shows strong results in relapsed/refractory CLL.
Worry ifTrial data shows weak efficacy or safety issues. This affects approval chances.
Why it matters: This partnership could help Nurix grow. It may also support its drug development plans.
Supportive ifA press release will confirm new steps or goals reached in the Roche partnership.
Worry ifNo updates or negative news regarding the Roche partnership in the next quarter.
Why it matters: Better operating income shows financial health. It also shows how well management is doing.
Supportive ifOperating income improves to less than -$80M in the next quarter.
Worry ifOperating income gets worse, going below -$92.5M next quarter.
Why it matters: This payment shows the partnership and helps Nurix's finances.
Supportive ifNurix receives the $700 million upfront payment as planned in Q3 2026.
Worry ifThe payment is delayed or not received, raising concerns about the partnership.
Why it matters: Revenue trends will show how well management's growth plans are working.
Worry ifQ3 revenue shows a decline worse than the previous quarter's $9 million.
Less concerning ifQ3 revenue stabilizes or grows compared to the previous quarter.
Why it matters: Good results could make bexobrutideg a top treatment for CLL.
Watch forPhase 1b results show an objective response rate above 90% in earlier lines of therapy.
Also watch forResults are not as good as expected. This shows possible effectiveness issues.